Novavax to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Operational Highlights on November 12, 2024
GAITHERSBURG, Md., Nov. 4, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its third quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Tuesday, November 12, 2024. Details of the event and replay are as follows:
Conference call details: | |
Date: | November 12, 2024 |
Time: | 8:30 a.m. U.S. ET |
URL to register phone: | |
Dial-in number: | (800) 836-8184 (Domestic) or |
(+1) (646) 357-8785 (International) | |
Webcast: |
- Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.
- Participants can also dial direct to be entered into the call by an operator and will be prompted to request to join the Novavax, Inc. call.
- To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast.
Replay details: | |
Date: | Available starting at 11:30 a.m. ET, November 12, 2024, until 11:59 p.m. U.S. ET, November 19, 2024 |
Dial-in number: | (888) 660-6345 (Domestic) or |
(+1) (646) 517-4150 (International) | |
Passcode: | 62491 # |
Webcast: | ir.novavax.com/events, until December 12, 2024 |
About Novavax
Novavax, Inc. (NASDAQ:NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Luis Sanay, CFA
240-268-2022
[email protected]
Media
Giovanna Chandler
202-709-5563
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-third-quarter-2024-financial-results-and-operational-highlights-on-november-12-2024-302295599.html
SOURCE Novavax, Inc.